Aura Biosciences, Inc. filed a Form 8-K on August 11, 2026, disclosing an organizational realignment, a planned workforce reduction of approximately 20%, the appointment of Susan Abu-Absi, Ph.D. as Chief Operating Officer, and the announcement of financial results for the quarter ended June 30, 2026.

Key Highlights

  • Workforce reduction: The company plans to reduce its workforce by approximately 20% as part of an organizational realignment focused on ocular oncology.
  • Restructuring costs: Total cash payments related to the realignment are estimated at approximately $2.9 million to $3.2 million, with a significant majority expected to be paid in the third quarter of 2026.
  • NMIBC program deprioritized: The company disclosed plans to "minimize resource allocation towards its non-muscle invasive bladder cancer ('NMIBC') program on a going forward basis."
  • New COO appointed: Susan Abu-Absi, Ph.D., age 52, was appointed Chief Operating Officer effective August 10, 2026.
  • COO base salary: Dr. Abu-Absi will receive an annual base salary of $520,000 and a target annual performance bonus of 45% of her base salary.
  • Equity award: The company intends to grant Dr. Abu-Absi approximately 400,000 shares of common stock, comprised of approximately 60% stock options and 40% restricted stock units.
  • Q2 2026 results announced: A press release covering financial results for the quarter ended June 30, 2026, was furnished as Exhibit 99.1.

Aura Biosciences Realigns Around Ocular Oncology, Appoints New COO

According to the filing, Aura Biosciences (NASDAQ:AURA) announced on August 11, 2026, an organizational realignment intended to "streamline its operating plan and organizational structure to focus resources in ocular oncology." As part of this realignment, the company disclosed plans to minimize resource allocation toward its NMIBC program going forward and to reduce its workforce by approximately 20%. Impacted employees are eligible for severance benefits contingent on execution and non-revocation of a severance agreement that includes a general release of claims against the company.

The company estimated total cash payments and costs related to the realignment at approximately $2.9 million to $3.2 million. The filing noted that "a significant majority of these amounts" are expected to be paid in the third quarter of 2026, and that "these estimates are subject to a number of assumptions and actual results may differ." The company also cautioned that additional costs not currently contemplated may be incurred.

Separately, the filing disclosed that the Board appointed Susan Abu-Absi, Ph.D. as Chief Operating Officer, effective August 10, 2026. Dr. Abu-Absi most recently served as Chief Operating Officer at Be Biopharma, Inc. from February 2025 to June 2026, and previously as Chief Technology Officer at 2seventy bio, Inc. from November 2021 to May 2024. She holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering from the University of Toledo. The planned equity grant of approximately 400,000 shares is structured with the option award vesting 25% on the first anniversary of the effective date, with 2.0834% vesting monthly over the following 36 months, and the RSUs vesting in four equal 25% annual installments beginning on the first anniversary of the 15th of the month in which the grant occurs.

What Was Disclosed

The 8-K covered three principal items: Q2 2026 financial results (furnished via press release), an organizational realignment with an estimated $2.9 million to $3.2 million cost and approximately 20% workforce reduction, and the appointment and compensation terms of a new Chief Operating Officer.